Purinergic Receptor Y8 (P2RY8) is a G-protein coupled receptor (GPCR) activated by lysophosphatidylserine (LysoPS). It plays a critical role in confining B cells within germinal centers. Dysregulation, deletions, or fusions involving P2RY8 (such as the P2RY8-CRLF2 fusion) are major drivers in B-cell acute lymphoblastic leukemia (B-ALL) and follicular lymphomas, making it an essential target for oncology and immunology research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for P2RY8 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | P2RY8 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for immunization and ELISA. |
View P2RY8 Products |
| Gene Delivery | P2RY8 Lentivirus Premade Particles Full-length ORF for stable cell line generation. Crucial for preserving native GPCR conformation in cell-based assays. |
View P2RY8 Products |
| Benchmark Ab | Anti-P2RY8 Recombinant Antibody Recombinant positive control for flow cytometry and binding assays. |
View P2RY8 Products |
| Validator | P2RY8 siRNA Set Target-specific knockdown verification in functional assays. |
View P2RY8 Products |
| Related Target A | CRLF2 Partner in the P2RY8-CRLF2 fusion gene, a critical prognostic marker and therapeutic target in pediatric B-ALL. |
View CRLF2 Products |
| Related Target B | GPR174 Co-receptor for LysoPS that shares overlapping immunosuppressive pathways in the tumor microenvironment. |
View GPR174 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPCR Conformation Loss in Soluble Formats | Lentivirus-mediated stable cell line expression to maintain native 7-transmembrane structure. |
| Subfamily Off-target Screening | Sequence-verified homolog panels (GPR174, P2RY10) strictly validated by mass spectrometry. |
| Lack of Controls | Clinical-grade benchmark antibodies included as reference standards. |
| False Positives in Functional Assays | Sequence-specific siRNA sets included for target knockdown validation. |
Live P2RY8 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of P2RY8 is expanding rapidly beyond its established role as a diagnostic marker in leukemia. While the P2RY8-CRLF2 fusion remains a primary target for pediatric B-ALL therapies, new research is focusing on P2RY8's role as a GPCR mediator in germinal center homing and immune evasion. The next wave of drug discovery is shifting toward small molecule modulators and monoclonal antibodies aimed at restoring normal lymphocyte migration or disrupting immunosuppressive LysoPS signaling in the tumor microenvironment.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies | Academic Medical Centers, Biotech Startups | B-cell Lymphoma, Follicular Lymphoma | Flow Cytometry validation (Requires high-titer Lentivirus for stable target-expressing cell lines) |
| Small Molecule Agonists/Antagonists | Pharmaceutical Research Institutes | Autoimmune Diseases, Solid Tumors | Functional GPCR screening (Requires Calcium Flux and cAMP assays via cell lines) |
| CAR-T / Bispecifics (targeting fusion partners) | Immunotherapy Developers | CRLF2/P2RY8+ B-ALL | Target specificity screening (Requires recombinant CRLF2 and P2RY8 antigens) |